Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IJ1D
|
|||
| Former ID |
DIB000398
|
|||
| Drug Name |
HuM-195-Bi-213
|
|||
| Synonyms |
SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Discontinued in Phase 1/2 | [1] | |
| Company |
PDL BioPharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008571) | |||
| REF 2 | Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.